Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function [5]

Journal of Clinical Psychopharmacology

Volumn 28, Issue 1, 2008, Pages 107-108

  Lavindran, Lakshmi N ^a,b   Eisfeld, Beata S ^a   Kennedy, Sidney H ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; MIRTAZAPINE;

ADULT; CLINICAL ARTICLE; CLINICAL FEATURE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG TOLERABILITY; FEMALE; HUMAN; LETTER; MALE; MONOTHERAPY; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

ADRENERGIC UPTAKE INHIBITORS; ADULT; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIANSERIN; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; THIOPHENES; TREATMENT OUTCOME;

EID: 38349153248     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318160d609     Document Type: Letter

References (13)

1. Nofzinger EA, Thase ME, Reynolds CF 3rd, et al. Sexual function in depressed men. Assessment by self-report, behavioral, and nocturnal penile tumescence measures before and after treatment with cognitive behavior therapy. Arch Gen Psychiatry. 1993;50:24-30.
2. Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 patients. J Clin Psychiatry. 2001;62:10-20.
3. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60mg once daily dosing in the acute treatment of major depression. J Psychiatr Res. 2002;36:383-390.
4. Schatzberg AF. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. J Clin Psychiatry. 2003;64(suppl 13):30-37.
5. Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in four double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry. 2005;66:686-692.
6. Gelenberg AJ, Laukes C, McGahuey C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry. 2000;61:356-360.
7. Koutouvidis N, Pratikakis M, Fotiadou A. The use of mirtazapine in a group of 11 patients following poor compliance to selective serotonin reuptake inhibitor treatment due to sexual dysfunction. Int Clin Psychopharmacol. 1999;14:253-255.
8. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
9. Kennedy SH, Fulton KA, Bagby RM, et al. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry. 2006;51:234-242.
10. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry. 2006;67(suppl 6):33-37.
11. Stimmel GL, Gutierrez MA. Sexual dysfunction and psychotropic medications. CNS Spectr. 2006;11(suppl 9):24-30.
12. Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs. 1996;5:389-402.
13. Munoz M, Bancroft J, Turner M. Evaluating the effects of an alpha-2 adrenoceptor antagonist on erectile function in the human male. 1. The erectile response to erotic stimuli in volunteers. Psychopharmacology. 1994;115:463-470.